DAPEFY 10 mg/100 mg/500 mg Tablets are a fixed-dose combination therapy designed for the management of type 2 diabetes mellitus. Each tablet contains: Dapagliflozin 10 mg – a sodium-glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion. Sitagliptin 100 mg – a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances incretin activity, stimulating insulin release and reducing glucagon levels. Metformin 500 mg – a biguanide that decreases hepatic glucose production and improves insulin sensitivity. This triple therapy provides complementary mechanisms of action to improve glycemic control, reduce cardiovascular risk, and support long-term diabetes management.
